share_log

レナサイエンス---大幅続伸、25年3月期業績を上方修正

Renaissance - significant increase, upward revision of performance for the fiscal year ending March 25th.

Fisco Japan ·  Jul 3 21:10


Significant continued growth. After the end of the transaction on the 3rd, an upward revision of business results was announced, and it was well received. Business revenue for the fiscal year ending 25/3 was revised upward from 90 million yen to 105 million yen, and ordinary profit and loss were revised upward from a deficit of 275 million yen to a deficit of 257 million yen, and the deficit was expected to shrink. The reason for the revision is that US Eirion Therapeutics, Inc., which has concluded a license agreement granting exclusive license for skin disease treatment RS5441 (transdermal drug, oral drug), has begun phase I clinical trials (transdermal drugs), so it is planned to receive 100,000 US dollars as a milestone.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment